Polyrizon partners with Clearmind to develop intranasal MEAI formulation
Go back to Polyrizon partners with Clearmind to develop intranasal MEAI formulation| (NASDAQ: CMND) | Delayed: 1.14 +0.06 (5.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.08 | 52 Week High | $ | |||
| Open | $1.11 | 52 Week Low | $ | |||
| Day High | $1.15 | P/E | N/A | |||
| Day Low | $1.09 | EPS | $ | |||
| Volume | 16,155 | |||||
| (NASDAQ: PLRZ) | Delayed: 13.11 -0.5 (3.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.61 | 52 Week High | $ | |||
| Open | $13.27 | 52 Week Low | $ | |||
| Day High | $14.00 | P/E | N/A | |||
| Day Low | $13.00 | EPS | $ | |||
| Volume | 23,152 | |||||
